2024-11-25 – Press Releases – www.prnewswire.com
SHANGHAI, Nov. 25, 2024 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus…